Form 13-F position report

FENNEC PHARMACEUTICALS INC

Reported by VANGUARD GROUP INC

FENC CUSIP 31447P100 Manager CIK 0000102909

Reported 1,026,654 shares, up 13,028 (1.3%) from the prior quarter.

Reported value -44.3%; share count 1.3% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 1,026,654 Quarter-end amount reported
Reported value $6,272,856 Fair value at quarter end
Consecutive quarters held 5 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 692000
2021-06-30 0
2023-06-30 705279
2023-09-30 614078
2023-12-31 12791507
2024-03-31 11271521
2024-06-30 6272856
2024-09-30 5239455
2024-12-31 6128845
2025-03-31 5874536
2025-06-30 8026864
2025-09-30 8945951
2025-12-31 8220912

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for FENNEC PHARMACEUTICALS INC held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Added 1,067,651 +111,887 (11.7%) < 0.01% $8,220,912 2026-01-29
Q3 2025 Reduced 955,764 -11,328 (-1.2%) < 0.01% $8,945,951 2025-11-07
Q2 2025 Added 967,092 +2,472 (0.3%) < 0.01% $8,026,864 2025-08-11
Q1 2025 Reduced 964,620 -5,134 (-0.5%) < 0.01% $5,874,536 2025-05-09
Q4 2024 Reduced 969,754 -78,137 (-7.5%) < 0.01% $6,128,845 2025-02-11
Q3 2024 Added 1,047,891 +21,237 (2.1%) < 0.01% $5,239,455 2024-11-13
Q2 2024 Added 1,026,654 +13,028 (1.3%) < 0.01% $6,272,856 2024-08-13
Q1 2024 Reduced 1,013,626 -126,437 (-11.1%) < 0.01% $11,271,521 2024-05-10
Q4 2023 Added 1,140,063 +1,058,295 (1294.3%) < 0.01% $12,791,507 2024-02-14
Q3 2023 Added 81,768 +1,895 (2.4%) < 0.01% $614,078 2023-11-14
Q2 2023 New 79,873 +79,873 (0.0%) < 0.01% $705,279 2023-08-14
Q2 2021 Reduced 0 -111,372 (-100.0%) 0 $0 2021-08-13
Q1 2021 Added 111,372 +13,864 (14.2%) < 0.01% $692,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

81 managers reported FENNEC PHARMACEUTICALS INC for Q2 2024.

Managers reporting FENNEC PHARMACEUTICALS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Southpoint Capital Advisors LP Unchanged 4,077,214 0 0.62% $24,911,778 28 qtrs
Sonic GP LLC Unchanged 2,407,357 0 30.37% $14,708,951 7 qtrs
DG Capital Management LLC Added 1,634,811 +123,148 3.85% $9,988,695 13 qtrs
Solas Capital Management LLC Added 1,340,000 +229,767 4.48% $8,187,400 21 qtrs
BlackRock Inc Added 1,187,242 +259,776 < 0.01% $7,254,049 25 qtrs
VANGUARD GROUP INC This report Added 1,026,654 +13,028 < 0.01% $6,272,856 5 qtrs
HARBERT FUND ADVISORS INC Unchanged 466,869 0 2.03% $2,852,570 13 qtrs
STATE STREET CORPORATION Added 321,206 +17,687 < 0.01% $1,962,569 5 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 301,578 +81,824 < 0.01% $1,842,640 17 qtrs
GENDELL JEFFREY L Reduced 283,365 -19,113 0.06% $1,731,360 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
16,552
None
1,010,102

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.